Overview

This is a cross-sectional study that will be conducted across Japan using an online patient-reported outcome questionnaire.

This study tries to find out the attitudes toward and experiences of the emotional and/or social impact of side effects associated with antifibrotic (AF) treatment among Japanese patients with Idiopathic Pulmonary Fibrosis (IPF)/Progressive Pulmonary Fibrosis (PPF), and how are these attitudes associated with patients' individual characteristics.

Eligibility

Inclusion Criteria:

1. Patients with IPF aged 40 years or older who received nintedanib or pirfenidone within the previous 4 weeks, or patients with PPF aged 18 years or older who received nintedanib within the previous 4 weeks
2. Patients capable of responding to a self-administered questionnaire

Exclusion Criteria:

1. Patients treated with nerandomilast (including clinical trials)
2. Patients with PPF treated with pirfenidone
3. Patients currently hospitalized
4. Patients with malignant tumors